UniQure

Activity by year

2020202120222023202420252026

Contract

Jun 25, 2020CONTRACT$450.0M
CSL Behring acquires global commercialization rights to uniQure's hemophilia B gene therapy AMT-061
CSL Behring acquired exclusive global rights to commercialize AMT-061, a gene therapy for hemophilia B, from uniQure. uniQure will receive an upfront payment of $450 million and additional royalties.
CSL Behring customer UniQure supplier #Medical Devices hemophilianewstoday.com
Jun 25, 2020CONTRACT$2.00B
UniQure grants CSL Behring global rights to hemophilia B gene therapy
UniQure granted CSL Behring exclusive global rights to commercialize its AAV gene therapy program AMT-061 for hemophilia B, in a licensing deal potentially worth up to $2 billion.
UniQure CSL Behring customer globalgenes.org

Customers

Loading…

UniQure: plants, expansions, contracts and acquisitions · Endata